FDA approves Invokana to treat type 2 diabetes
First in a new class of diabetes drugs FDA NEWS RELEASE: 29/3/2013 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm
Leggi
European Medicines Agency recommends restricting use of cilostazol-containing medicines
22 March 2013 - EMA/98571/2013 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Cilostazol-containing_medicines/human_referral_000338.jsp&mid=WC0b01ac05805c516f
Leggi
Comunicato Stampa EMA sull’uso concomitante di medicinali che agiscono sul sistema renina – angiotensina (RAS) (17/05/2013)
http://www.agenziafarmaco.gov.it/sites/default/files/RAS-acting_agents_-_comunicato%20EMA%5B1%5D.pdf
Leggi
Comunicazione AIFA
Precisazione AIFA su Incretine 20/05/2013 http://www.agenziafarmaco.gov.it/it/content/precisazione-aifa-su-incretine-0
Leggi
European Medicines Agency – Outcome of review of new safety data on insulin glargine
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2013 EMA/329790/2013 http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500143823
Leggi
ADA/EASD Recommendations for Clinicians and People with Diabetes Concerning the Use of Incretin Therapy and Pancreatic Disease
27 giugno 2013 http://easd.org/index.php?option=com_content&view=article&id=172
Leggi
FDA Drug Safety Communication: FDA requires label warnings to prohibit sharing of multi-dose diabetes pen devices among patients
25/02/2015 http://www.fda.gov/Drugs/DrugSafety/ucm435271.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
Leggi
The Committee for Medicinal Products for Human Use (CHMP) recommended the addition of a new formulation to the marketing authorisation of Optisulin (insulin glargine) and a change of its invented name to Toujeo.
The new formulation of Toujeo is a higher-strength insulin (300 units/ml) 26/02/2015 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000309/smops/Positive/human_smop_000789.jsp&mid=WC0b01ac058001d127
Leggi
An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment
Makam AN and Nguyen OK
Circulation 2017;135:180-95
Leggi
The Diabetic HFpEF Phenotype: Is it Real and is it Worth Targeting Therapeutically?
Lindman BR
Circulation. Pub. online January 4, 2017
Leggi